- Home
- MGX
MGX
METAGENOMI INC
as 06-20-2025 4:00pm EST
Stocks
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 62.1M | IPO Year: | 2024 |
| Target Price: | $13.00 | AVG Volume (30 days): | 417.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $5.50 | Next Earning Date: | 08-13-2025 |
| Revenue: | $45,263,000 | Revenue Growth: | -4.22% |
| Revenue Growth (this year): | -35.02% | Revenue Growth (next year): | 11.75% |
Stock Insider Trading Activity of METAGENOMI INC (MGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Noonberg Sarah B. | MGX | Chief Medical Officer | Jun 6 '25 | Sell | $1.75 | 5,239 | $9,168.25 | 109,135 | |
| Irish Jian | MGX | See Remarks | Jun 6 '25 | Sell | $1.75 | 6,390 | $11,182.50 | 315,543 | |
| Wapnick Pamela | MGX | Chief Financial Officer | Jun 6 '25 | Sell | $1.75 | 1,576 | $2,758.00 | 72,108 |
Latest METAGENOMI INC News
MGX Breaking Stock News: Dive into MGX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
MT Newswires
a month ago
Chardan Cuts Price Target on Metagenomi to $12 From $13, Keeps Buy Rating
GlobeNewswire
a month ago
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
Zacks
a month ago
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
a month ago
Metagenomi: Q1 Earnings Snapshot
GlobeNewswire
a month ago
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
Zacks
a month ago
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Metagenomi to Present at Upcoming Scientific Meetings
Compare MGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGX METAGENOMI INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.